Apatinib for Resectable Colorectal Cancer

Sponsor
Nanchong Central Hospital
Study ID
NCT03228043
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib combine with CAPEOX adjuvant chemotherapy for resectable colorectal
  • CAPEOX — DRUG
    CAPEOX adjuvant chemotherapy for resectable colorectal

Study Details

Objective: To compare the outcome of patients with colorectal cancer who treated with adjuvant therapy or Apatinib with adjuvant therapy postoperatively. Language: English.

Key Dates

Start date
Mar 1, 2020
Status verified
Nov 2024
Primary completion
Mar 1, 2021
Completion
Mar 1, 2023

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib group
    Apatinib combined with CAPEOX program. Apatinib tablets: 500 mg po qd from the second cycle of chemotherapy. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
  • Placebo Comparator: Control group
    CAPEOX program. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.

Primary Outcome Measure

Number of Participants recurrence-free survival [ Time Frame: 1 year ]

Related Studies